Canada’s Drug Agency recommended conditional public reimbursement for palopegteriparatide (Yorvipath) on September 3, giving adults with chronic hypoparathyroidism that conventional calcium and calcitriol therapy fails to control a realistic path to funded access. The conditions attached to the recommendation matter: coverage is not automatic, and negotiated price will almost certainly determine how quickly provincial formularies act.
The recommendation follows a clinical record built largely on the Phase 3 PaTHway trial, which tracked sustained response in adults with hypoparathyroidism across three years. That durability argument carries weight in a condition where patients typically cycle through high-dose calcium and calcitriol indefinitely, often with incomplete symptom control and persistent hypocalcemia risk. Ascendis Pharma had already secured FDA approval in August 2024, so the Canadian agency had a substantial post-approval evidence base to evaluate, not just trial data.
The practical bottleneck now is price negotiation with the pan-Canadian Pharmaceutical Alliance. CDEC conditional recommendations routinely stall at that stage, and chronic hypoparathyroidism affects a small patient population, which cuts both ways: the per-patient budget impact is manageable, but the absence of a large comparator pool makes cost-effectiveness modeling contentious. Natpara (recombinant human PTH 1-84) is the established hormonal alternative against which payers will benchmark value, and its formulary history across Canadian provinces will shape how aggressively they negotiate.
The clinical team to watch is the one managing patients who meet the “inadequate control” threshold the recommendation defines. That eligibility criterion will be the operational gate: if the bar is drawn narrowly around documented hypocalcemia episodes or hospitalization, uptake stays limited regardless of reimbursement status. How the final coverage criteria define “inadequately controlled” is the single specification worth tracking as provincial decisions follow.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
